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INTRODUCTION
Neuropathies are routinely classified as demyelinating or
axonal, based on the presence or absence of
demyelinating abnormalities on electrodiagnostic testing.
The presence of conduction block/temporal dispersion
reflects acquired nature of immune neuropathies and has
been reported in patients with generalized, distal and
asymmetric phenotypic pictures.    Chronic acquired
immune polyneuropathies are heterogeneous group of
disorders, which may present in a variety of ways, besides
the typical symmetric pattern observed in Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP). It is
therefore important to appreciate different clinical
presentations of underly ing immune mediated
neuropathies because majority of these are potentially
treatable entities.
MATERIAL AND METHODS
Place of study
This study was carried out at Jinnah Post Graduate
Medical Centre in Karachi over a period of 2 years from
June 2006 to June 2008. This was a prospective clinical
study.
Inclusion criteria
All the adult male and female patients who presented with
chronic proximal and/or distal weakness of more then one
limbs in symmetric or asymmetric fashion were included in
the study.
Exclusion criteria
Any of the patients with one or more of the following
features was excluded from the study:
1) History of diabetes mellitus, uremia, chronic liver 
disease or alcoholism.
2) Positive family history of similar illness.
3) Any patient with foot deformities, sphincter 
impairment, mutilation of hands and feet, 
icthyosis, or retinitis pigmentosa.
4) History of drug or toxic exposure likely to cause 
neuropathy.
Methods
Patients with chronic acquired neuropathies with
neurophysiological features of segmental demyelination in
any combination, i.e. conduction block (CB), slowing of
conduction across the affected segment (proximal and/or
distal), prolonged distal latency and/or temporal dispersion
(TD) were evaluated over a period of 2 years. Those who
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ABSTRACT
Objective: To determine the different clinical presentations of patients with acquired immune mediated neuropathies.
Methodology: This was a hospital based prospective study over a period of 2 years in a series of patients with
electrophysiological evidence of chronic acquired immune neuropathies. Results: Males out-numbered females by 7 (19 vs
12). Majority of patients with chronic acquired immune neuropathies were found to have typical symmetric sensorimotor
pattern with variable involvement of proximal and distal muscles. The sensory pattern was the next common pattern
followed by asymmetric pattern consistent with madsaM neuropathy. Conclusion: Because immune mediated neuropathies
are potentially treatable entities, it is essential to keep in mind their unusual presentations besides the typical symmetric
pattern of weakness of limb girdle muscles.
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met revised neurophysiological criteria (Nicolas et al.) for
CIDP were clinically categorized into different groups.
The following segments were considered for analysis: tibal
(ankle and popliteal fossa), peroneal (ankle and below the
fibular head), ulnar (wrist and below elbow), and median
nerve (wrist and elbow). Electro diagnostic changes that
were considered features of demyelination were similar to
those proposed by American Academy of Neurology (AAN)
committee (AAN, 2001), but with more stringent criteria
for partial conduction block/temporal dispersion (NICOLAS
ET AL). Revised neurophysiological criteria by Nicolas et al.
were categorized into following four groups.
GROUP 1:
CB/TD must be present in one nerve and abnormal
conduction values in at least two other nerves.
GROUP 2:
CB/TD must be present in two different nerves and
abnormal conduction values in one other nerve.
GROUP 3:
CB/TD present in at least 3 different nerves with abnormal
conduction values suggesting demyelination in at least
one nerve including one of the nerves with CB/TD.
GROUP 4:
No CB/TD but abnormal conduction values must be
present in three different nerves.
CSF Study was also performed in all the patients and
those with CSF content of more than 100 mg/dl were
categorized as having high protein content.
The muscle strength was measured manually in abductors
of shoulders, flexors and extensors of neck, elbows, wrists,
fingers, hips, ankles and toes by means of the Medical
Research Council (MRC) scale. 
Functional impairment was assessed with modified Rankin
Disability scale:
0) Asymptomatic.
1) Non-Disabling symptoms that don’t interfere with 
activities of daily living..
2) Slight Disability (unable to carry out all activities, 
such as running, but still able to look after 
themselves).
3) Moderate disability (but able to walk without 
assistance).
4) Moderately severe disability (unable to walk 
without assistance).
5) Severe Disability (Dependant)
For purpose of analysis patients with generalized (pattern)
neuropathy were defined as having either symmetric
proximal weakness or proximal plus distal weakness of
major muscle groups.
Patients with distal pattern were defined as having
symmetric distal large fiber sensory loss (Romberg’s
positive) or glove stocking numbness with or without distal
weakness.
The asymmetric neuropathy was defined as having motor
asymmetry, which differs by at least one grade in a
minimum of 2 muscle groups, based on the MRC scale.
RESULTS
1) Age and Sex
Out of total 31 patients, 19 were males and 12 were
females. Patients were categorized into different age
groups where in majority were found between 40-60 years
of age.
2)  Clinical Variant
Of the 31 patients, majority of patients were found to have
generalized pattern followed by distal pattern.
3)  CSF Analysis
CSF analysis revealed protein concentration of <100
mg/dl in majority of patients. Four out of 7 patients with
distal pattern had CSF protein concentration >100 mg/dl.
4)    Weakness pattern in different Variants
Out of 21 patients with generalized pattern, 10 has
equally symmetric proximal as well as distal weakness
followed by proximal > distal pattern. Patients with distal
TABLE 1. Demographic details and distribution of various clinical
variants of neuropathy in the sample population.
Male Female Total
n=19(%) n=12(%) n=31(%)
Under 30 2(10.5%) 1(8.3%) 3(9.7%)
30-39 5(26.3%) 2(16.7%) 7(22.6%)
40-49 1(5.3%) 6(50.0%) 7(22.6%)
50-59 8(42.1%) 2(16.7%) 10(32.3%)
60 & above 3(15.8%) 1(8.3%) 4(12.9%)
CIDP 12(63.2%) 9(75.0%) 21(67.7%)
MADSAM 1(5.3%) 1(8.3%) 2 (6.5)
DADS 5(26.3%) 2(16.7%) 7(2.3%)
MMCB 1 (2.3%) 0 1(13.2%)
Age
Clinical
Variant
pattern were found to be more ataxic rather than having
glove and stocking sensory pattern.
5)    Functional state
Majority of patients with generalized pattern were found to
have moderate disability compared to distal pattern who
were mainly found to have slight disability.
6)    Electro-diagnostic Criteria
Patients with generalized pattern were found to have
CB/TD in majority of cases (group 2 & 3). CB/TD was
infrequent with distal pattern of CIDP.
DISCUSSION
CIDP is a cl inical ly heterogeneous group of
polyneuropathies united by their presumed immune
mediated etiopathogenesis. In clinical practice, it is
unusual to take into consideration different clinical
phenotypes of CIDP while coming across patients with
neuropathic symptoms. However distinction between
these subgroups is of immediate practical relevance to
patient management.2 The disorders, which have some
characteristics unique but otherwise have clinical,
electrophysiologic, laboratory and therapeutic aspects
similar to CIDP, are considered variants.1
Since the first consensus criteria proposed by the
American Academy of Neurology in 1991, numerous
authors have proposed alternative ones.10 However as
there is no gold standard parameter for diagnosis of CIDP,
we selected the proposed revised electrophysiological
criteria by Nicolas et al.  for diagnostic purpose.5
The disease is believed to more likely affect all age groups
but is more common in older males.7 Our study found
similar pattern wherein 21/31 patients were above 40 at
the time of diagnosis. CIDP is traditionally distinguished
from chronic length dependent polyneuropathies by
uniform muscle weakness (proximal as well as distal) of
upper and lower limb with generalized areflexia.10
Similar pattern of global weakness of upper and lower
limbs was noticed in majority of our patients (32%)
followed by proximal more than distal (22.6%) and then
distal more than proximal (12%) patterns. Thus it is
important to keep in mind that predominant proximal or
distal weakness with hyporeflexia or areflexia with or
without sensory symptoms may be presenting patterns of
CIDP.
As CIDP is heterogeneous in presentation with unusual
patterns like ataxic and distal asymmetric variants,8 we
also came across such patterns in our series of patients.
Typically a pure or predominant sensory presentation have
also been reported to occur in presence of marked motor
nerve slowing with relative preservation of motor function.
Our patients with DADS pattern were ataxic in 42% (3/7)
of case whereas pure distal numbness was found in 28%
(2/7) of cases .One patient in this group was found to
have more distal sensory motor involvement of hands than
feet.
Two out of thirty patients were found to have distal
asymmetric pattern, proportion corresponding to series of
patients studied by M. Bushby et al.2
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TABLE 2. Clinical spectrum of various neuropathies
CIDP MADSAM DADS MMCB
n=21 n=2 n=7 n=1
Distribution
of 
Weakness
Functional
Status
CSF
Protein
(mg/l)
Electro
Diagnostic
Criteria
(Nicolas et al.)
Proximal=
Distal
(P=D)
10
(47.6%)
Proximal>
Distal
(P>D)
Distal>
Proximal
(D>P)
Slight
disability
(grade 2)
Moderate
disability
(grade 3)
Distal
Ataxic
Distal
Numbness
Distal
(UL)
Grade 1
Under 50
51-100
>100
Grade 2
Grade 3
Grade 4
Asymmetric
(D/P)
Severe
Disability
(grade 4)
6
(28.6%)
5(23.8%)
9(42.9%)
2(2.5%)
1(50%)
1(50%)6(28.6%)
6(28.6%)
3(14.3%)
5(23.8%)
10(47.6%)
6(28.6%)
2(29%)
4(57%)
1(100%)
1(50%)
1(50%)
1(14%)
10
(47.6%)
1(50%)
1(50%)
5(71%)
2(29%)
6(86%)
1(14%)
1(100%)
1(100%)
1(14%)
3(43%)
2(29%)
1(14%) 1(100%)
2(100%)
CSF study was carried out in all patients and interestingly,
the proportion of patient with protein content of more than
100 mg/dl was higher in those with DADS than in those
with typical CIDP pattern. This needs further elucidation.
Because conduction block and temporal dispersion are
highly suggestive of segmental demyelination, therefore
we selected the proposed revised neurophysiological
criteria by Nioles et al. which gives special emphasis to
markers of demyelination.5
It came to our notice that patients with diffuse weakness
were found to have increased proportion of patients with
CB/TD than those with distal sensory or ataxic patterns.
This observation suggests that all electrophysiologic
features of demyelination are important to look for in
diagnostic neurophysiologic studies.
The aim of this study was to enhance awareness about
clinical profile of CIDP, which is usually considered uniform
and symmetric neuropathic entity.
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